Literature DB >> 23601810

Development of amyloid burden in African Green monkeys.

Sergey Kalinin1, Stephanie L Willard, Carol A Shively, Jay R Kaplan, Thomas C Register, Matthew J Jorgensen, Paul E Polak, Israel Rubinstein, Douglas L Feinstein.   

Abstract

The vervet is an old world monkey increasingly being used as a model for human diseases. In addition to plaques and tangles, an additional hallmark of Alzheimer's disease is damage to neurons that synthesize noradrenaline (NA). We characterized amyloid burden in the posterior temporal lobe of young and aged vervets, and compared that with changes in NA levels and astrocyte activation. Total amyloid beta (Aβ)40 and Aβ42 levels were increased in the aged group, as were numbers of amyloid plaques detected using antibody 6E10. Low levels of Aβ42 were detected in 1 of 5 younger animals, although diffusely stained plaques were observed in 4 of these. Increased glial fibrillary acidic protein staining and messenger RNA levels were significantly correlated with increased age, as were cortical NA levels. Levels of Aβ42 and Aβ40, and the number of 6E10-positive plaques, were correlated with NA levels. Interestingly messenger RNA levels of glial derived neurotrophic factor, important for noradrenergic neuronal survival, were reduced with age. These findings suggest that amyloid pathology in aged vervets is associated with astrocyte activation and higher NA levels. Published by Elsevier Inc.

Entities:  

Keywords:  African Green monkey; Alzheimer's disease; Amyloid; Noradrenaline; Vervet

Mesh:

Substances:

Year:  2013        PMID: 23601810      PMCID: PMC3706498          DOI: 10.1016/j.neurobiolaging.2013.03.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  56 in total

1.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

Review 2.  Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?

Authors:  Paul J Fitzgerald
Journal:  Curr Alzheimer Res       Date:  2010-09       Impact factor: 3.498

Review 3.  The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits.

Authors:  Xuan Ye; Wenjiao Tai; Dan Zhang
Journal:  Neurobiol Aging       Date:  2011-12-31       Impact factor: 4.673

4.  Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex.

Authors:  Eoin N McNamee; Eadaoin W Griffin; Karen M Ryan; Katie J Ryan; Sheena Heffernan; Andrew Harkin; Thomas J Connor
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

5.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

6.  Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.

Authors:  Mikko Airavaara; Olga Pletnikova; Maire E Doyle; Yong E Zhang; Juan C Troncoso; Qing-Rong Liu
Journal:  J Biol Chem       Date:  2011-11-11       Impact factor: 5.157

7.  A non-human primate system for large-scale genetic studies of complex traits.

Authors:  Anna J Jasinska; Michelle K Lin; Susan Service; Oi-Wa Choi; Joseph DeYoung; Olivera Grujic; Sit-Yee Kong; Yoon Jung; Mathew J Jorgensen; Lynn A Fairbanks; Trudy Turner; Rita M Cantor; Jessica Wasserscheid; Ken Dewar; Wesley Warren; Richard K Wilson; George Weinstock; J David Jentsch; Nelson B Freimer
Journal:  Hum Mol Genet       Date:  2012-05-03       Impact factor: 6.150

8.  7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

9.  Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration.

Authors:  R Elrod; E R Peskind; L DiGiacomo; K I Brodkin; R C Veith; M A Raskind
Journal:  Am J Psychiatry       Date:  1997-01       Impact factor: 18.112

10.  Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge.

Authors:  Joan B O'Sullivan; Karen M Ryan; Andrew Harkin; Thomas J Connor
Journal:  J Neuroimmunol       Date:  2010-01-12       Impact factor: 3.478

View more
  17 in total

1.  Specific amyloid β clearance by a catalytic antibody construct.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Sari Sonoda; Yan Lin; Hiroaki Taguchi; Mariko Hara; Steven Kolodziej; Yukie Mitsuda; Veronica Gonzalez; Hameetha B R Sait; Ken-ichiro Fukuchi; Richard J Massey; Robert P Friedland; Brian O'Nuallain; Einar M Sigurdsson; Sudhir Paul
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 2.  Alzheimer's disease: experimental models and reality.

Authors:  Eleanor Drummond; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2016-12-26       Impact factor: 17.088

Review 3.  Comparative Approaches to Understanding the Relation Between Aging and Physical Function.

Authors:  Jamie N Justice; Matteo Cesari; Douglas R Seals; Carol A Shively; Christy S Carter
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-04-23       Impact factor: 6.053

4.  Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta).

Authors:  Kara B Duffy; Balmiki Ray; Debomoy K Lahiri; Edward M Tilmont; Gregory P Tinkler; Richard L Herbert; Nigel H Greig; Donald K Ingram; Mary Ann Ottinger; Julie A Mattison
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

5.  Pair housing of Vervets/African Green Monkeys for biomedical research.

Authors:  Matthew J Jorgensen; Kelsey R Lambert; Sarah D Breaux; Kate C Baker; Beverly M Snively; James L Weed
Journal:  Am J Primatol       Date:  2015-11-05       Impact factor: 2.371

6.  Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Mariko Hara; Sari Sonoda; Sarah K Murphy; Kenji Watanabe; Yukie Mitsuda; Eric L Brown; Richard J Massey; Stanley R Primmer; Brian O'Nuallain; Sudhir Paul
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

Review 7.  Aging-related Alzheimer's disease-like neuropathology and functional decline in captive vervet monkeys (Chlorocebus aethiops sabaeus).

Authors:  Brett M Frye; Suzanne Craft; Caitlin S Latimer; C Dirk Keene; Thomas J Montine; Thomas C Register; Miranda E Orr; Kylie Kavanagh; Shannon L Macauley; Carol A Shively
Journal:  Am J Primatol       Date:  2021-04-05       Impact factor: 2.371

Review 8.  Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases.

Authors:  Jean-Michel Verdier; Isabelle Acquatella; Corinne Lautier; Gina Devau; Stéphanie Trouche; Christelle Lasbleiz; Nadine Mestre-Francés
Journal:  Front Neurosci       Date:  2015-03-04       Impact factor: 4.677

Review 9.  Comparative neuropathology in aging primates: A perspective.

Authors:  Carmen Freire-Cobo; Melissa K Edler; Merina Varghese; Emily Munger; Jessie Laffey; Sophia Raia; Selena S In; Bridget Wicinski; Maria Medalla; Sylvia E Perez; Elliott J Mufson; Joseph M Erwin; Elaine E Guevara; Chet C Sherwood; Jennifer I Luebke; Agnès Lacreuse; Mary A Raghanti; Patrick R Hof
Journal:  Am J Primatol       Date:  2021-07-13       Impact factor: 2.371

10.  Neurodegenerative disease biomarkers Aβ1-40, Aβ1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy.

Authors:  Jason A Chen; Scott C Fears; Anna J Jasinska; Alden Huang; Noor B Al-Sharif; Kevin E Scheibel; Thomas D Dyer; Anne M Fagan; John Blangero; Roger Woods; Matthew J Jorgensen; Jay R Kaplan; Nelson B Freimer; Giovanni Coppola
Journal:  Brain Behav       Date:  2018-01-13       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.